Literature DB >> 25458226

Ultrasound screening of contralateral breast after surgery for breast cancer.

Seung Ja Kim1, Se-Yeong Chung2, Jung Min Chang2, Nariya Cho2, Wonshik Han3, Woo Kyung Moon4.   

Abstract

OBJECTIVE: To determine whether supplemental screening ultrasound (US) to mammography could improve cancer detection rate of the contralateral breast in patients with a personal history of breast cancer and dense breasts.
MATERIALS AND METHODS: During a one-year study period, 1314 screening patients with a personal history of breast cancer and dense breasts simultaneously underwent mammography and breast US. BI-RADS categories were given for mammography or US-detected lesions in the contralateral breast. The reference standard was histology and/or 1-year imaging follow-up, and the cancer rate according to BI-RADS categories and cancer detection rate and positive biopsy rate according to detection modality were analyzed.
RESULTS: Of 1314 patients, 84 patients (6.4%) were categorized as category 3 with one interval cancer and one cancer which was upgraded to category 4A after 6-month follow-up US (2.5% cancer rate, 95% CIs 1.5-9.1%). Fifteen patients (1.1%) had category 4A or 4B lesions in the contralateral breast. Four lesions were detected on mammography (two lesions were also visible on US) and 11 lesions were detected on US and 5 cancers were confirmed (33.3%, 95% CIs 15.0-58.5%). Six patients (0.5%) had category 4C lesions, 2 detected on mammography and 4 on US and 4 cancers were confirmed (66.7%, 95% CIs 29.6-90.8%). No lesions were categorized as category 5 in the contralateral breast. Cancer detection rate by mammography was 3.3 per 1000 patients and that by US was 5.0 per 1000 patients, therefore overall cancer detection rate by mammography plus US was 8.3 per 1000 patients. Positive biopsy rate of mammography-detected lesions was 66.7% (4 of 6) and that of US-detected lesions was 40.0% (6 of 15).
CONCLUSION: US can be helpful to detect mammographically occult breast cancer in the contralateral breast with high positive biopsy rate and low category 3 rate in patients with a previous history of breast cancer and dense breasts.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  BI-RADS category; Breast cancer; Contralateral breast; Mammography; Ultrasonography; Ultrasound breast screening

Mesh:

Year:  2014        PMID: 25458226     DOI: 10.1016/j.ejrad.2014.09.019

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  6 in total

1.  Cumulative Risk Distribution for Interval Invasive Second Breast Cancers After Negative Surveillance Mammography.

Authors:  Janie M Lee; Linn Abraham; Diana L Lam; Diana S M Buist; Karla Kerlikowske; Diana L Miglioretti; Nehmat Houssami; Constance D Lehman; Louise M Henderson; Rebecca A Hubbard
Journal:  J Clin Oncol       Date:  2018-05-02       Impact factor: 44.544

2.  Breast Cancer Screening With Mammography Plus Ultrasonography or Magnetic Resonance Imaging in Women 50 Years or Younger at Diagnosis and Treated With Breast Conservation Therapy.

Authors:  Nariya Cho; Wonshik Han; Boo-Kyung Han; Min Sun Bae; Eun Sook Ko; Seok Jin Nam; Eun Young Chae; Jong Won Lee; Sung Hun Kim; Bong Joo Kang; Byung Joo Song; Eun-Kyung Kim; Hee Jung Moon; Seung Il Kim; Sun Mi Kim; Eunyoung Kang; Yunhee Choi; Hak Hee Kim; Woo Kyung Moon
Journal:  JAMA Oncol       Date:  2017-11-01       Impact factor: 31.777

Review 3.  How do women at increased breast cancer risk perceive and decide between risks of cancer and risk-reducing treatments? A synthesis of qualitative research.

Authors:  Hannah G Fielden; Stephen L Brown; Pooja Saini; Helen Beesley; Peter Salmon
Journal:  Psychooncology       Date:  2017-01-26       Impact factor: 3.894

4.  Imaging Surveillance for Survivors of Breast Cancer: Correlation between Cancer Characteristics and Method of Detection.

Authors:  A Jung Chu; Jung Min Chang; Nariya Cho; Woo Kyung Moon
Journal:  J Breast Cancer       Date:  2017-06-26       Impact factor: 3.588

Review 5.  Detection of 14-3-3 sigma (σ) promoter methylation as a noninvasive biomarker using blood samples for breast cancer diagnosis.

Authors:  Meng Ye; Tao Huang; Ying Ying; Jinyun Li; Ping Yang; Chao Ni; Chongchang Zhou; Si Chen
Journal:  Oncotarget       Date:  2017-02-07

6.  Feasibility of abbreviated magnetic resonance imaging (AB-MRI) screening in women with a personal history (PH) of breast cancer.

Authors:  Yeong Yi An; Sung Hun Kim; Bong Joo Kang; Young Jin Suh; Ye Won Jeon
Journal:  PLoS One       Date:  2020-03-12       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.